Sararwut Jaimassiri / Shutterstock.com
11 March 2016Americas
Let CRISPR/Cas9 battle commence
The US Patent and Trademark Office (USPTO) has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
13 January 2016 Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.
Europe
29 October 2015 Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements.
Americas
14 April 2016 Regeneron Pharmaceuticals has agreed a licensing deal that it says will enable it to advance CRISPR/Cas gene-editing technology.
Editor's picks
Editor's picks
Americas
13 January 2016 Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.
Europe
29 October 2015 Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements.
Americas
14 April 2016 Regeneron Pharmaceuticals has agreed a licensing deal that it says will enable it to advance CRISPR/Cas gene-editing technology.
Americas
13 January 2016 Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.
Europe
29 October 2015 Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements.
Americas
14 April 2016 Regeneron Pharmaceuticals has agreed a licensing deal that it says will enable it to advance CRISPR/Cas gene-editing technology.